Serenella M. Pupa and Elda Tagliabue contributed equally to this work.
HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine†
Article first published online: 10 MAY 2005
Copyright © 2005 Wiley-Liss, Inc.
Journal of Cellular Physiology
Volume 205, Issue 1, pages 10–18, October 2005
How to Cite
Pupa, S. M., Tagliabue, E., Ménard, S. and Anichini, A. (2005), HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. J. Cell. Physiol., 205: 10–18. doi: 10.1002/jcp.20387
- Issue published online: 27 JUL 2005
- Article first published online: 10 MAY 2005
- Manuscript Accepted: 1 FEB 2005
- Manuscript Received: 18 JAN 2005
- Associazione Italiana per la Ricerca sul Cancro and FIRB-MIUR. Grant Number: RBNE017B4C
The oncoprotein encoded by the HER-2 oncogene is a member of the HER family of receptor tyrosine kinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER-2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor-specific therapy. In addition, HER-2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell-mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER-2 in breast cancer. © 2005 Wiley-Liss, Inc.